These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 33098047)
1. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. Fukudo M; Tamaki G; Azumi M; Kakizaki H; Matsumoto S; Tasaki Y Invest New Drugs; 2021 Apr; 39(2):595-604. PubMed ID: 33098047 [TBL] [Abstract][Full Text] [Related]
2. Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. Beinse G; Hulin A; Rousseau B Invest New Drugs; 2019 Dec; 37(6):1289-1291. PubMed ID: 30806848 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960 [TBL] [Abstract][Full Text] [Related]
4. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968 [TBL] [Abstract][Full Text] [Related]
5. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454 [TBL] [Abstract][Full Text] [Related]
6. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184 [TBL] [Abstract][Full Text] [Related]
7. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205 [TBL] [Abstract][Full Text] [Related]
8. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113 [TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N; Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135 [TBL] [Abstract][Full Text] [Related]
11. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408 [TBL] [Abstract][Full Text] [Related]
13. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031 [TBL] [Abstract][Full Text] [Related]
14. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667 [TBL] [Abstract][Full Text] [Related]
15. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172 [TBL] [Abstract][Full Text] [Related]
16. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893 [TBL] [Abstract][Full Text] [Related]
17. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146 [TBL] [Abstract][Full Text] [Related]
18. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma. Henriksen JN; Andersen CU; Fristrup N Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681 [TBL] [Abstract][Full Text] [Related]
20. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma. Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T Clin Genitourin Cancer; 2019 Feb; 17(1):e1-e11. PubMed ID: 30529389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]